News
Biotechnology Act submitted for public consultation.
On 4 August, the Biotechnology Act was submitted for public consultation.
As indicated in the call for comments, the new European Biotechnology Act was announced in the political guidelines for the European Commission for 2024–2029. This initiative aims to facilitate the path of biotechnology from research laboratories to production facilities and then to market. Biotechnology, supported by AI and digital tools, can help modernise entire sectors of the economy, from agriculture and forestry to energy and healthcare. In 2022, the gross value added of biotechnology in the EU was €38.1 billion: medical and pharmaceutical biotechnology made the largest contribution, while industrial biotechnology grew the fastest.
The overall objective of the initiative is to improve the size and competitiveness of the biotechnology sector in the EU while maintaining high safety standards. The new European Biotechnology Act aims to ensure that the EU makes the most of the biotechnology revolution for the benefit of society, the environment and the economy. The Act aims to facilitate the development and marketing of products in all biotechnology sectors in the EU.
According to the information provided on the website, the consultation is aimed at citizens, innovators, entrepreneurs, industry, financial institutions, investors/venture capitalists, researchers/research organisations, civil society (including consumer, patient and environmental organisations), other users of biotechnology (e.g. farmers and foresters), trade unions, national and regional authorities, and any other interested parties.
To participate, please complete the online questionnaire. Responses can be submitted in any official EU language.
The public consultation will run until 10 November 2025. The Commission plans to adopt the act in the third quarter of 2026.
Link to the consultation: